Boulder-based Clovis Oncology, a developer of anti-cancer drugs, is expected to debut in an IPO on the market this week on the NASDAQ Global Market, under the ticker symbol CLVS. Clovis--which set its initial pricing range at between $13.00 and $15.00 per share on October 31st--has raised $146.3M in venture capital funding since its founding in 2009. The firm's IPO is being underwritten by J.P. Morgan and Credit Suisse, and the company is backed by Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, and Abingworth Bioventures, along with Pfizer.
Top NewsTuesday, November 15, 2011
Clovis Oncology On Tap For IPO